Probiotic solution for allergic rhinitis

Key marketing aspects

  • targeting the most commen allergic disease
  • unique combination of patented probiotic strains selected for restoring the allergic immune system
  • reducing both eye and nasal symptoms in perennial rhinits
  • improving quality of life during allergy season (even in subjects using pharmacotherapy)
  • natural alternative to pharmacotherapy
  • clinically tested in children & adults
  • pharmacy exclusive


  • 3 randomized clinical trials published reporting improvements in a total of 305 subjects treated with Rhinozyn
  • significant reduction of clinical symptoms of perennial rhinitis1,2
  • significant improvement of quality of life (RQLQ) in seasonal rhinitis3
  • stimulating the Th1 immune response and reducing IgE synthesis6
  • vitamin D modulates the immune response and is associated with aeroallergen sensitization and allergic rhinitis4


  • children & adults
  • once a day
  • long-term use
  • stand-alone or add-on to pharmacotherapy


  1. Peng et al., Pediatr Allergy Immunol (2005)
  2. Wang et al., Pediatr Allergy Immunol (2004)
  3. Costa et al., Eur J Clin Nutr (2014)
  4. Aryan et al., Int Rev Immunol (2017)
  5. Mutgi & Koo, Pediatr Dermatol (2013)
  6. Hsu et al. US 6,994,848 B2 (2006)

Rhinozyn® is exclusively marketed by BLUESTONE PHARMA GmbH, contact: info@bluestone-pharma.com